Uncategorized

Uncategorized

AI Drug Development: FDA Releases Draft Guidance

FDA AI Draft Guidance – On January 6, 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products.” This document outlines the types of information the FDA may require when evaluating the use of Artificial Intelligence […]

Uncategorized

What are common mistakes to avoid during FDA inspections?

Preparing for and undergoing an FDA inspection can be a daunting process for companies, especially those operating in highly regulated industries such as pharmaceuticals, medical devices, and food production. Despite their best efforts, many companies make mistakes during FDA inspections that can lead to warning letters, fines, or even product recalls. Below, we highlight the

Uncategorized

How to Access FDA Inspection Report Quickly?

tl;dr: To access FDA inspection reports quickly, explore Atlas Compliance—a leading regulatory inspection intelligence platform. With an extensive database, advanced AI features, and detailed inspector profiles, Atlas ensures life science companies stay ahead in compliance. Download reports, request missing documents, and unlock actionable insights for your business. Streamline Your Compliance: Quickly Access FDA Inspection Reports

Uncategorized

What Is Atlas Compliance, and How Does It Help Life Science Companies?

In the life sciences industry, maintaining compliance with regulatory bodies like the FDA is not just a responsibility—it’s a necessity. Companies must meet stringent standards to ensure their products are safe, effective, and manufactured in controlled conditions. However, navigating these compliance requirements can often feel like walking through a maze. That’s where Atlas Compliance steps

Uncategorized

Why FDA 483 Observations Will Be on the Rise in 2025?

FDA 483 Observations are projected to rise in 2025 due to increased regulatory scrutiny, evolving compliance standards, and a surge in inspections post-pandemic. Companies must prioritize compliance by implementing robust quality systems, conducting regular audits, and addressing issues proactively. Failure to comply can lead to Warning Letters, tarnished reputations, and operational halts. Prevention lies in

Uncategorized

How to Address and Prevent FDA Form 483 Observations?

tl;dr: FDA Form 483 observations highlight GMP non-compliance during FDA inspections. Common issues include equipment, documentation, processes, training, and facility controls. Prevent them through proactive management, strong documentation, training, audits, and compliance tools. Atlas simplifies compliance by automating insights and improving inspection readiness. What Is FDA Form 483 Observations?  FDA Form 483 observations are official

Uncategorized

Unexo’s Operations Questioned as FDA Lists 12 Compliance Issues 

tl;dr: Unexo, an over-the-counter drug manufacturer, recently faced scrutiny during an FDA inspection conducted from May 1, 2024, to May 14, 2024, led by inspectors Nicole Knowlton and Kellia Hicks. This inspection led to the Warning Letter by the USFDA ranging from inadequate documentation to improper facility maintenance. This article breaks down the key observations

Scroll to Top